Ceftolozane

證據等級: L5

預測適應症: 10 個

Ceftolozane: From Complicated Urinary Tract Infections to Gonococcal Urethritis

One-Sentence Summary

Ceftolozane is a novel semisynthetic cephalosporin (β-lactam) antibiotic, clinically deployed as the Ceftolozane/tazobactam combination (Zerbaxa), approved in the US and EU for complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) — though not currently registered in Taiwan.

The TxGNN model predicts it may be effective for Gonococcal Urethritis, with a prediction score of 99.89%; however, no clinical trials and no publications currently exist in this data set to support this direction, placing the evidence entirely at the model-prediction tier.

Quick Overview

Item	Content
Original Indication	Complicated urinary tract infections (cUTI) including pyelonephritis; complicated intra-abdominal infections (cIAI) — as Ceftolozane/tazobactam combination
Predicted New Indication	Gonococcal Urethritis
TxGNN Prediction Score	99.89%
Evidence Level	L5
Taiwan Market Status	✗ Not registered
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Ceftolozane is a β-lactam antibiotic of the cephalosporin class. Its primary mechanism involves inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) — particularly PBP1b, PBP1c, and PBP3 — thereby disrupting peptidoglycan crosslinking and triggering cell lysis. It is always co-administered with tazobactam, a β-lactamase inhibitor that shields Ceftolozane from enzymatic degradation by extended-spectrum β-lactamases (ESBLs). The combination demonstrates exceptional potency against multidrug-resistant Pseudomonas aeruginosa and other difficult gram-negative pathogens.

The mechanistic link to gonococcal urethritis is conceptually plausible. Neisseria gonorrhoeae is a gram-negative diplococcus that possesses PBPs and is theoretically susceptible to β-lactam antibiotics targeting the same pathway. Furthermore, treatment-resistant gonorrhea — including strains failing ceftriaxone, the current first-line therapy — represents an urgent unmet public health need. Some in vitro data (not captured in this data set) suggest Ceftolozane achieves low MIC values against N. gonorrhoeae, making it a candidate of interest for drug-resistant gonococcal infections.

That said, translating in vitro susceptibility to clinical utility for urethritis requires additional considerations: the standard of care for uncomplicated gonorrhea is oral or single-dose IM therapy, whereas Ceftolozane/tazobactam is administered intravenously, limiting its practicality in outpatient STI settings. The TxGNN score of 99.89% most likely reflects the model’s recognition of the shared gram-negative pathogen class between approved and predicted indications, rather than indication-specific clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered for Ceftolozane in Gonococcal Urethritis.

Literature Evidence

Currently no related literature available for Ceftolozane in Gonococcal Urethritis.

Taiwan Market Information

Ceftolozane is currently not registered in Taiwan. The Taiwan FDA (TFDA) has issued no marketing authorizations for Ceftolozane or Ceftolozane/tazobactam products. Safety data including prescribing warnings and contraindications from the TFDA package insert are therefore unavailable and represent a blocking data gap (DG001).

Safety Considerations

Please refer to the Ceftolozane/tazobactam SmPC (EU) or US Prescribing Information for safety information. Key safety data including TFDA warnings, contraindications, and drug-drug interactions were not available in this evidence pack and must be retrieved before clinical decision-making.

Conclusion and Next Steps

Decision: Hold

Rationale: Although the mechanistic rationale connecting Ceftolozane’s PBP-inhibitory activity to N. gonorrhoeae is pharmacologically coherent — and the public health urgency of drug-resistant gonorrhea provides genuine motivation — the complete absence of clinical trials and published literature (L5 evidence) means this prediction cannot advance beyond a research hypothesis at this time. Additionally, the IV-only route of administration creates a practical barrier for an outpatient STI indication.

To proceed, the following is needed:

MIC / in vitro susceptibility data: Obtain or commission minimum inhibitory concentration studies of Ceftolozane against clinical N. gonorrhoeae isolates, with priority on ceftriaxone-resistant strains
MOA confirmation (DG002): Retrieve full mechanism of action and PBP-binding profile from DrugBank to confirm coverage of N. gonorrhoeae-specific PBP variants
TFDA prescribing information (DG001): Download and parse TFDA SmPC equivalent to identify contraindications and warnings before any safety assessment can proceed
Route compatibility assessment: Evaluate whether IV Ceftolozane/tazobactam is clinically appropriate for the urethritis indication (outpatient vs. hospitalized patients)
Systematic literature review: Search for Ceftolozane activity against sexually transmitted gram-negative pathogens outside the current data set (e.g., ESCMID, IDSA conference abstracts)
Regulatory precedent scan: Review whether any regulatory agency has evaluated Ceftolozane/tazobactam for STI indications as part of a drug-resistant gonorrhea emergency use pathway
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.